NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced that it will participate in the 2023 Biotech Showcase, to be held on January 9-11, at Hilton San Francisco Union Square, in San Francisco, CA.
On Tuesday, January 10, at 11:00 AM ET, Byung Ha Lee, Ph.D., Chief Scientific Officer of NIT, will present “T cell Amplification: Curative Therapeutics for Cancer Patients”. His presentation will cover the clinical development of NT-I7 (efineptakin alfa, a long-acting human IL-7), its combination program with checkpoint inhibitors, and the biomarker data in NT-I7 combo therapy.
The details of the company’s presentations are as follows:
2023 Biotech Showcase
- Speaker: Byung Ha Lee, Ph.D., Cheif Science officer
- Title: T cell Amplification: Innovative Therapeutics for Cancer Patients
- Date: Tuesday, January 10
- Time: 11:00 AM (EST)
Media inquiries : email@example.com